NR AWQO
AU Wilson,S.M.; Oliver,J.; Lane,A.; Patel,J.; Dealler,S.; Rosedale,R.; Stanley,C.
TI Application of the seprion ligand in prion disease
QU International Conference - Prion 2006: Strategies, advances and trends towards protection of society - 3.10.-6.10.2006, Torino, Italy, Lingotto Conference Centre - Poster sessions DIA-61
PT Konferenz-Poster
AB
Previously, we have described the development of a PrPsc-specific ligand, Seprion, into a very simple microplate immunoassay which removes the need for sample preparation, including proteinase K. When used as a post-mortem brain assay this Seprion assay has 100% sensitivity and specificity compared to current gold standards (Ref. 1) and has received USDA approval for use in CWD and BSE and EU approval for use in scrapie (including atypical scrapie) and BSE. Recently, we have been investigating the utility of the ligand in an ante-mortem blood screening assay and in a therapeutic compound screening assay. Previously, we have presented the results of a small blind study on whole blood from scrapie-infected and uninfected sheep received frozen from the Veterinary Laboratories Agency (VLA) archive. In this study the assay had a sensitivity of 100% and a specificity of 96%. We have further developed this assay into a format appropriate for use in ante-mortem animal diagnostics and for use by human blood screening services. The results of screening a larger blind panel of sheep plasma samples and a large number of samples from a scrapie infection time course study will be presented. The assay has also been used to screen a large number of compounds for activity in vitro in the prevention of amyloid protein aggregation. A number of compounds were identified, some of which were also found to reduce scrapie prion load in infected neuronal cell lines. We conclude that the Seprion ligand is a versatile tool that can be incorporated into: post-mortem brain, lymph node and spleen assays; an ante-mortem plasma assay; and a therapeutic compound screening assay.
References 1. Lane, A; Stanley, C; Dealler, S; Wilson, S.M. 2003. Clin. Chem., 49, 1774-1775.
AD Microsens Biotechnologies, London, NW1 0NH, UK. E-mail: info@microsens.co.uk
SP englisch
PO Italien